Phase 1 Study of BTK Inhibitor in Treating B-cell Blood Cancers Underway, TG Therapeutics Announces
News
A Phase 1 clinical trial, sponsored by TG Therapeutics, is recruiting patients with B-cell lymphoma or leukemia to study the company’s Bruton tyrosine kinase (BTK) inhibitor, TG-1701. The study is enrolling up ... Read more